Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Mar 02, 2016
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Feb 22, 2016
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Feb 19, 2016
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced that the U.S. Food and Drug Administration (the "FDA") has accepted the
Jan 29, 2016
The study is being conducted under Special Protocol Assessment (SPA) agreement with the FDA . This registrational, randomized, controlled Phase 3 study (ADVANCE) will evaluate SPI-2012 as a treatment for chemotherapy-induced neutropenia in approximately 580 patients with breast cancer.
Jan 11, 2016
HENDERSON, Nev. & LAVAL, Quebec --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology and Servier Canada Inc.
Dec 16, 2015
Registrational, randomized, active-controlled Phase 3 study (ADVANCE) will study SPI-2012 as a treatment for chemotherapy-induced neutropenia in approximately 580 patients with breast cancer. The company expects to start the pivotal trial soon and plans to complete enrollment in 2017.
Dec 08, 2015
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its
Dec 06, 2015
Data was Highlighted in an Oral Presentation of a Phase 1 Study at the 57th Annual Meeting of the American Society of Hematology (ASH) Study Shows 86% Objective Response Rate with 67% Complete Responses in Newly Diagnosed Patients with Peripheral T-cell Lymphoma (PTCL) At Full Dose Intensity the
Dec 04, 2015
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its
Nov 20, 2015
Spectrum Plans to Initiate a 70 Patient U.S. Based Breast Cancer Phase 2 Study as Soon as Possible Poziotinib Has Already Been Studied in Multiple Cancer Types in over 250 Patients and Has Shown Activity in Breast Cancer, Lung Cancer and Gastric Cancer Poziotinib Has Shown a Remarkable 60% Response
Nov 18, 2015
Spectrum to receive an up-front payment of $15 million plus $5 million in profits on initial ZEVALIN supply HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in
Nov 04, 2015
Spectrum Has Potential to Earn Up to $22 Million in Combination of Base Fee and Identified Milestone Payments With Strong Pharmaceutical and Oncology Focused Expertise, Spectrum's 32-Person Corporate Accounts Sales Team Poised to Commercialize up to Six Eagle Products In Addition, Eagle to Hire up
Nov 04, 2015
Company met with the FDA , made significant progress, and is ready to initiate SPI-2012 Pivotal clinical trial upon agreement on Special Protocol Assessment (SPA) On track for apaziquone NDA filing by year end based on previous Phase 3 studies; additional Phase 3 trial initiated under SPA Meeting
Nov 02, 2015
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Oct 26, 2015
Company on Track for Apaziquone NDA Filing Based on Prior Phase 3 Data by Year End Learnings From Prior Trials and Agreement with the FDA Through a Special Protocol Assessment (SPA) Incorporated into Study Design Pivotal Study Would Satisfy FDA's Requirement of Initiating an Additional Phase 3
Oct 23, 2015
The FDA did not identify any clinical deficiency in the CRL Company plans to meet with FDA and seek clarification on the CRL HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a
Sep 03, 2015
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Sep 02, 2015
Published Data Highlights Achievement of Myeloablation (Median Day 5) and Engraftment (Median Day 12-13) with no mortality (Day 100) EVOMELA is Free of Propylene Glycol, a Diluent Required for Reconstitution of Current Melphalan Formulations that is Associated with Renal and Cardiac Toxicities
Aug 17, 2015
Company is on Track for Apaziquone NDA Filing by Year End Based on Pooled Data from Two Completed Phase 3 Studies that Showed a Statistically Significant Reduction in 2-Year Recurrence Rates (p-value = 0.0218) Learnings From Earlier Phase 3 Program and FDA's Comments Incorporated in New Phase 3
Aug 06, 2015
SPI-2012 : Pursuing Special Protocol Assessment (SPA) before initiating a non-inferiority Phase 3 study, also powered at 80% for superiority to pegfilgrastim EVOMELA ™ (melphalan hydrochloride) for injection: On track for FDA decision (NDA PDUFA date of October 23, 2015 ) Poziotinib : Expect to
Displaying 121 - 140 of 791